FAQ

EMD 273063 antibody, human

Known as: Hu 14.18/IL - 2 Fusion Protein, hu14.18-interleukin-2 fusion protein, EMD 273063 
A recombinant protein consisting of the hu14.18 monoclonal antibody fused to the cytokine interleukin-2 (IL2) with potential antineoplastic activity… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2014
012320002014

Related topics

Related topics

7 relations
Cytotoxic T-LymphocytesReceptor Activation ProcessT-Cell Activationantigen binding
(More)

Broader (2)

Interleukin-2Monoclonal Antibodies

Related mentions per year

Related mentions per year

1948-2018
19401960198020002020
EMD 273063 antibody, human
Monoclonal Antibodies
Cytotoxic T-Lymphocytes
T-Cell Activation
Receptor Activation Process
Interleukin-2

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Vaccination with anti-idiotype antibody ganglidiomab mediates a GD2-specific anti-neuroblastoma immune response
Immunotherapy targeting disialoganglioside GD2 emerges as an important treatment option for neuroblastoma, a pediatric malignancy… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
Phase I testing of the hu14.18-IL2 immunocytokine in melanoma patients showed immune activation, reversible toxicities, and a… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2011
2011
Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface
The huKS-IL2 immunocytokine (IC) consists of IL2 fused to a mAb against EpCAM, while the hu14.18-IL2 IC recognizes the GD2… (More)
  • figure 1
  • figure 3
  • figure 4
  • figure 5
  • figure 7
Is this relevant?
2010
2010
Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.
Response to immunocytokine (IC) therapy is dependent on natural killer cells in murine neuroblastoma (NBL) models. Furthermore… (More)
  • table 3
  • table 4
  • table 5
  • table 7
  • table 6
Is this relevant?
2009
2009
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
To explore the biological activity of EMD 273063 (hu14.18-IL2), a humanized anti-GD2 monoclonal antibody fused to interleukin-2… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2008
2008
Intratumoral immunocytokine treatment results in enhanced antitumor effects
Immunocytokines (IC), consisting of tumor-specific monoclonal antibodies fused to the immunostimulatory cytokine interleukin 2… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2006
2006
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
PURPOSE Evaluate the clinical safety, toxicity, immune activation/modulation, and maximal tolerated dose of hu14.18-IL2 (EMD… (More)
  • table 2
  • table 3
  • table 4
  • table 5
  • table 6
Is this relevant?
2004
2004
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
PURPOSE To evaluate the safety, toxicity, in vivo immunologic activation, and maximum-tolerated dose (MTD) of EMD 273063 (hu14.18… (More)
Is this relevant?
2004
2004
Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
Established s.c. NXS2 murine neuroblastoma tumors exhibited transient resolution after suboptimal therapy using the hu14.18-IL2… (More)
Is this relevant?
2003
2003
NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy
We evaluated recurrent NXS2 neuroblastoma tumors that developed following NK- or T-cell–mediated immunotherapy in tumor-bearing… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?